Detection of Escherichia coli and Associated β-Lactamases Genes from Diabetic Foot Ulcers by Multiplex PCR and Molecular Modeling and Docking of SHV-1, TEM-1, and OXA-1 β-Lactamases with Clindamycin and Piperacillin-Tazobactam

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Shahi, Shailesh K ^a   Singh, Vinay K ^a   Kumar, Ashok ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 15; BETA LACTAMASE OXA 1; BETA LACTAMASE SHV; BETA LACTAMASE SHV 1; BETA LACTAMASE TEM 1; CEFAZOLIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CLINDAMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; GENOMIC DNA; HYDROGEN; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATION; BLA OXA GENE; BLA SHV GENE; BLA TEM GENE; DIABETIC FOOT; DISEASE SEVERITY; ENZYME SYNTHESIS; ESCHERICHIA COLI; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; HYDROGEN BOND; MAJOR CLINICAL STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; SKIN BIOPSY; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CLINDAMYCIN; DIABETIC FOOT; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENE EXPRESSION; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; MULTIPLEX POLYMERASE CHAIN REACTION; PENICILLANIC ACID; PIPERACILLIN; STRUCTURAL HOMOLOGY, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

ESCHERICHIA COLI;

EID: 84879803803     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068234     Document Type: Article

References (53)

1. Icks A, Haastert B, Trautner C, Giani G, Glaeske G, et al. (2009) Incidence of lower-limb amputations in the diabetic compared to the non-diabetic population. Findings from nationwide insurance data, Germany, 2005-2007. Exp Clin Endocrinol Diabetes 117: 500-504.
2. Shobhana R, Rao PR, Lavanya A, Vijay V, Ramachandran A, (2000) Cost burden to diabetic patients with foot complications- a study from southern India. J Assoc Physicians India 48: 1147-1150.
3. Adler AI, Boyko EJ, Ahroni JH, Smith DG, (1999) Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 22: 1029-1035.
4. Wagner FW, (1981) The dysvascular foot: a system for diagnosis and treatment. Foot Ankle 2: 64-122.
5. Armstrong DG, Lavery LA, Nixon BP, Boulton AJM, (2004) It's not what you put on, but what you take off: techniques for debriding and offloading the diabetic foot wound. Clin Infect Dis 39: S92-99.
6. Urbancic-Rovan V, Gubina M, (1997) Infections in diabetic patients: The role of anaerobes. Clin Infect Dis 25: S184-185.
7. Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, et al. (2006) A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care 29: 1727-1732.
8. Gupta V, Datta P, Singla N (2008) Skin and soft tissue infection: frequency of aerobic bacterial isolates and their antimicrobial susceptibility pattern. J Assoc Physicians India 56.
9. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y, (2005) High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 49: 2137-2139.
10. Bradford PA, (2001) Extended spectrum β-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14: 933-951.
11. Chaudhary U, Agarwal R, (2004) Extended spectrum-lactamases (ESBL)- an emerging threat to clinical therapeutics. Ind J Med Microbiol 22: 75-80.
12. Paterson DL, Bonomo RA, (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18: 657-86.
13. Coque TM, Baquero F, Canton R, (2008) Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 13: 1-11.
14. Bauer RW, Kirby MDK, Sherris JC, Turck M, (1966) Antibiotic susceptibility testing by standard single disc diffusion method. Amer J Clin Pathol 45: 493-496.
15. Clinical Laboratory Standard Institute (2010) Performance standards for antimicrobial susceptibility testing. CLSI Approved Standards M100-S20. Wayne, PA. USA: CLSI.
16. Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, et al. (1987) Transferable enzymatic resistance to third-generation cephalosporins during a nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 8: 302-306.
17. Coudron PE, Moland ES, Sanders CC, (1997) Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J Clin Microbiol 35: 2593-2597.
18. Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, et al. (2007) Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 45: 199-205.
19. Clinical and Laboratory Standards Institute (2010) Screening and confirmatory tests for suspected carbapenemases production. Vol: 20 Supplemental Table 2A-S2. Wayne, PA, USA: CLSI.
20. Dallenne C, Costa AD, Decre D, Favier C, Arlet G, (2010) Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother 65: 490-495.
21. Solovyev V, Kosarev P, Seledsov I, Vorobyev D, (2006) Automatic annotation of eukaryotic genes, pseudogenes and promoters. Genome Biol 7: 1-10.
22. Quevillon E, Silventoinen V, Pillai S, Harte N, Mulder N, et al. (2005) InterProScan: protein domains identifier. Nucl Acids Res 33: 116-120.
23. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 22: 4673-4680.
24. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
25. Bailey TL, Williams N, Misleh C, Li WW, (2006) MEME: discovering and analyzing DNA and protein sequence motifs. Nucl Acids Res 34: 369-373.
26. Gao YD, Huang JF, (2011) An extension strategy of Discovery Studio 2.0 for non-bonded interaction energy automatic calculation at the residue level. Zool Res 32: 262-266.
27. Shahi SK, Singh VK, Kumar A, Singh SK, Gupta SK, (2012) Interaction of dihydrofolate reductase and aminoglycoside adenyltransferase enzyme from Klebsiella pneumoniae strain DF12SA with clindamycin: a molecular modelling and docking study. J Mol Model 19: 973-983.
28. Laskowski RA, Chistyakov VV, Thornton JM, (2005) D266-8 PDBsum more: new summaries and analyses of the known 3D structures of proteins and nucleic acids. Nucl Acids Res 33: 266-268.
29. Lovell SC, Davis IW, Arendall III WB, de Bakker PIW, Word JM, et al. (2002) Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Protein Struct Funct Genet 50: 437-450.
30. Maiti R, Van Domselaar GH, Zhang H, Wishart DS, (2004) SuperPose: a simple server for sophisticated structural superposition. Nucl Acids Res 32: W590-594.
31. Murugan S, Jayanthi, Devi PU, John PN (2011) Prevalence and antimicrobial susceptibility pattern of extended spectrum beta-lactamases producing Escherichia coli in diabetic foot infection. Res J Microbiol DOI: 10.3923/jm.2011: 1-9.
32. Alavi SM, Khosravi AD, Sarami A, Dashtebozorg A, Montazeri EA, (2007) Bacteriologic study of diabetic foot ulcer. Pak J Med Sci 235: 681-684.
33. Motta RN, Oiveira MM, Magallaes PS, Dias AM, Aragao LP, et al. (2003) Plasmid mediated extended spectrum beta-lactamase producing strains of Enterobacteriaceae isolated from Diabetes foot infection. Braz J Infect Dis 2: 129-134.
34. Mathai D, Rhomberg PR, Bledenbach DJ, Jones RN, (2002) Evaluation of the in vitro activity of six broad-spectrums beta-lactam antimicrobial agents against recent clinical isolates from India; A survey of ten medical center laboratories. Diagn Microbiol Infect Dis 44: 367-377.
35. Mansouri M, Ramazanzadeh R, (2009) Spread of extended-spectrum β-lactamase producing Escherichia coli clinical isolates in Sanandaj hospitals. J Biol Sci 9: 362-366.
36. Sana T, Rami K, Racha B, Fouad D, Marcel A, et al. (2011) Detection of genes TEM, OXA, SHV and CTX-M in 73 clinical isolates of Escherichia coli producers of extended spectrum β-lactamases and determination of their susceptibility to antibiotics. Int Arab J Antimicrob Agent 1: 1-6 doi:10: 3823/704.
37. Shanmugam P, Jeya M, Linda SS, (2013) The bacteriology of diabetic foot ulcers, with a special reference to multidrug resistant strains. J Clin Diagn Res 7: 441-445.
38. Sahu S, Panda PL, Mohanty I, Narasimham MV, Pasupalak S, (2011) Prevalence of carbapenem resistant gram negative bacilli from clinical samples. Ind Med Gazette 12: 461-464.
39. Selvakumar BN, Jasmine R, (2007) Antibiotic susceptibility of ESBL-producing urinary isolates at a tertiary care hospital in Tiruchirappali, South India. J Med Sci 7: 443-446.
40. Arabaci F, Oldacay M, Berber D, (2009) Evaluation of ESBL positivity rates for Escherichia coli and Klebsiella pneumoniae strains with the sensititre ESBL antimicrobic susceptibiity plates in a public hospital, Turkey. J Med Sci 9: 103-107.
41. Baudry PJ, Nichol K, DeCorby M, Lagace-Wiens P, Olivier E, et al. (2009) Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America. Diagn Microbiol Infect Dis 63: 319-326.
42. Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P, (2008) Molecular characterization and epidemiology of extended-spectrum ß-lactamase producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. Antimicrob Agents Chemother 52: 2818-2824.
43. Poirel L, Heritier C, Tolun V, Nordmann P, (2004) Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48: 15-22.
44. Bos F, Pleiss J, (2008) Conserved water molecules stabilize the Omega-loop in class A beta-lactamases. Antimicrob Agents Chemother 52: 1072-1079.
45. Majiduddin FK, Materon IC, Palzkill TG, (2002) Molecular analysis of beta-lactamase structure and function. Int J Med Microbiol 292: 127-137.
46. Ambler RP, (1980) The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 289: 321-331.
47. Bush K, Jacoby GA, Medeiros AA, (1995) A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39: 1211-1233.
48. Mitsuhashi S, Inoue M (1981) Mechanisms of resistance to beta-lactam antibiotics. New York: Springer-Verlag.
49. Matagne A, Misselyn-Bauduin AM, Joris B, Erpicum T, Granier B, et al. (1990) The diversity of the catalytic properties of class A beta-lactamases. Biochem J 265: 131-146.
50. Sun T, Nukaga M, Mayama K, Braswell EH, Knox JR, (2003) Comparison of β-lactamases of classes A and D: 1.5-A° crystallographic structure of the class D OXA-1 oxacillinase. Protein Sci 12: 82-91.
51. Pattanaik P, Bethel CR, Hujer AM, Hujer KM, Distler AM, et al. (2009) Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone. J Biol Chem 284: 945-953.
52. Ness S, Martin R, Kindler AM, Paetzel M, Gold M, et al. (2000) Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 beta-lactamase. Biochemistry 39: 5312-5321.
53. Shakil S, Khan AU, (2010) Interaction of CTXM15 enzyme with cefotaxime: a molecular modelling and docking study. Bioinformation 4: 468-472.